Abstracts tagged "treatment and uveitis"

Abstract Number: 67 • 2017 Pediatric Rheumatology Symposium
Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors
Courtney McCracken¹, Curtis Travers¹, Kirsten Jenkins², Carolyn Drews-Botsch³, Steven Yeh⁴, Sampath Prahalad^1,5 and Sheila Angeles-Han^6,7, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁴Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁵Pediatrics, Emory Children's Center, Atlanta, GA, ⁶Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Pediatrics, University of Cincinnati, Cincinnati, OH
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor-α inhibitors (TNFi) are common treatments for children with chronic non-infectious uveitis (NIU). Optimal duration of treatment prior to…
Abstract Number: 417 • 2016 ACR/ARHP Annual Meeting
Use of Tumor Necrosis Factor-α Inhibitors in Pediatric HLA-B27-Associated Uveitis
Bessie Frias¹, Courtney McCracken², Kirsten Jenkins³, Janet Figueroa⁴, Anna Tramposch¹, Steven Yeh⁵, Purnima Patel⁴, Carolyn Drews-Botsch⁶, Sampath Prahalad^7,8 and Sheila Angeles-Han^2,7, ¹Emory University, Atlanta, GA, ²Pediatrics, Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁶Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁷Children's Healthcare of Atlanta, Atlanta, GA, ⁸Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Pediatric HLA-B27-associated uveitis is a common form of non-infectious uveitis (NIU) that can lead to ocular complications and vision loss. Methotrexate (MTX) is the…
Abstract Number: 2945 • 2016 ACR/ARHP Annual Meeting
Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”
Ana Urruticoechea-Arana¹, Tatiana Cobo-Ibáñez², Virginia Villaverde García³, Montserrat Santos-Gómez⁴, Kelly Vargas Osorio⁵, Federico Díaz-González⁶, Leslie Fariñas Padrón⁵, Vanesa Calvo-Río⁷ and Ricardo Blanco Alonso⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain, ⁴Rheumatology, Hospital Can Misses, Ibiza, Spain, ⁵Family and Community Medicine, Hospital Can Misses, Ibiza, Spain, ⁶Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose:
Abstract Number: 2426 • 2015 ACR/ARHP Annual Meeting
Medication Taper and Risk of Relapse in Pediatric Uveitis
Sheila T. Angeles-Han^1,2,3, Courtney McCracken³, Steven Yeh², Daneka Stryker⁴, Kirsten Jenkins¹, Steven Tommasello⁵, Scott R. Lambert², Carolyn Drews-Botsch⁶ and Sampath Prahalad⁷, ¹Children's Healthcare of Atlanta, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵University of Alabama, Birmingham, AL, ⁶Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁷Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Pediatric uveitis can be vision-threatening. Treatment typically consists of ocular steroids, methotrexate, and anti-tumor necrosis factor (TNF) agents. Optimal duration of treatment and risk…
Abstract Number: 2439 • 2015 ACR/ARHP Annual Meeting
Methotrexate Failure in Pediatric Uveitis
Courtney McCracken¹, Steven Yeh², Kirsten Jenkins³, Daneka Stryker⁴, Steven Tommasello⁵, Curtis Travers¹, Scott R. Lambert², Carolyn Drews-Botsch⁶ and Sheila T. Angeles-Han^1,2,3, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ⁵University of Alabama, Birmingham, AL, ⁶Epidemiology, Emory University School of Public Health, Atlanta, GA
Background/Purpose: Pediatric uveitis can lead to ocular complications and vision loss. Treatment consists of steroid drops, methotrexate (MTX), and anti-tumor necrosis factor (TNF) drugs. Only…
Abstract Number: 1251 • 2014 ACR/ARHP Annual Meeting
Efficacy of Certolizumab in Patients with Refractory Uveitis to Other Biologic Therapy. Study of 7 Cases
Montserrat Santos-Gómez¹, Victor Llorens², Marina Mesquida², Ricardo Blanco¹, Vanesa Calvo-Río¹, Olga Maíz³, Ana Blanco⁴, Maite Sainz de la Maza², Alfredo Adan², Leyre Riancho-Zarrabeitia¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ⁴Ophthalmology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain
Background/Purpose Anti-TNF-α therapy may be useful in cases of uveitis refractory to standard synthetic immunosuppressive drugs. Infliximab (IFX) and adalimumab (ADA) are the biologic agents…
Abstract Number: 1249 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab in Patients with Uveitis Refractory to Other Biologic Drugs: A Multicenter Study on 31 Cases
Leyre Riancho-Zarrabeitia¹, Vanesa Calvo-Río¹, Ricardo Blanco¹, Inmaculada Calvo², Emma Beltrán-Catalán³, Alfredo Adan⁴, Marina Mesquida⁴, Maria Victoria Hernández⁵, Marisa Hernández⁶, Antonio Atanes-Sandoval⁷, Luis Francisco Linares Ferrando⁸, Olga Maiz Alonso⁹, Ana Blanco¹⁰, Beatriz Bravo¹¹, Gisela Díaz-Cordovés¹², Trinitario Pina¹, Montserrat Santos-Gómez¹ and Miguel A González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Pediatric Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain, ³Rheumatology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁴Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ⁶Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, ⁷Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, ⁸Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, ⁹Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹⁰Ophthalmology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, ¹¹Pediatrics, Hospital Virgen de las Nieves. Granada, Granada, Spain, ¹²Rheumatology, Hospital Regional Universitario (Carlos Haya). Málaga. Spain., Málaga, Spain
Background/Purpose: To evaluate the clinical response and safety of Tocilizumab (TCZ) in a series of patients with non-infectious uveitis refractory to other biologic drugs.Methods: Multicenter…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].